Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by University of Illinois at Chicago.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT00716586
First received: July 14, 2008
Last updated: NA
Last verified: July 2008
History: No changes posted

July 14, 2008
July 14, 2008
October 2005
October 2011   (final data collection date for primary outcome measure)
Decrease in the size of cystic macular lesions as tested by OCT [ Time Frame: 4-6 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

Seven patients with X-linked retinoschisis were treated with dorzolamide and the response to this treatment was monitored using OCT. These patients were also tested for the causative gene mutation and the resultant mechanism of functional loss of retinoschisin. It was observed that a response to dorzolamide may be seen irrespective of the mechanism that leads to decrease in function of retinoschisin.

Not Provided
Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Juvenile X-Linked Retinoschisis
Drug: dorzolamide
2% dorzolamide- 1 Gtt TID
Experimental: 1
Patients over the age of 18 years with juvenile X-linked retinoschisis
Intervention: Drug: dorzolamide
Walia S, Fishman GA, Molday RS, Dyka FM, Kumar NM, Ehlinger MA, Stone EM. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin. Am J Ophthalmol. 2009 Jan;147(1):111-115.e1. Epub 2008 Oct 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
Not Provided
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of cystic lesions on OCT testing

Exclusion Criteria:

  • Allergic reaction to sulpha containing compounds
  • Intolerance to dorzolamide
Male
18 Years and older
No
Contact: Gerald A Fishman, MD 312.996.8939 gerafish@uic.edu
United States
 
NCT00716586
IRB-2005-0551
Not Provided
Gerald Fishman, MD, University of Illinois at Chicago
University of Illinois at Chicago
Not Provided
Not Provided
University of Illinois at Chicago
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP